On February 27, 2018, AXIM® Biotechnologies (OTC:AXIM) announced the innovation of a new method to extract and micro-encapsulate cannabinoid molecules for a variety of pharmaceutical delivery formats from medicinal cannabis. The breakthrough makes AXIM the only company in the world with the ability to harness the proprietary procedure and provide Active Pharmaceutical Ingredients (“APIs”) of like purity from naturally extracted sources.
The secretive process, which was developed and tested in the Netherlands under strict regulatory guidelines, involves the growth of selected cannabis plants followed by extraction of the cannabinoid molecules from cannabis flowers in a process that employs just two steps in order to achieve an average of more than 99% purity (unlike traditional methods that include toxic solvents and multiple steps to produce the final extract or synthesize an API). AXIM’s newly developed microencapsulation method is then applied to the cannabinoids, protecting those from oxidation and degradation, while preserving its effectiveness. Finally, AXIM’s microencapsulated cannabinoids are manufactured into pharmaceutical products within different delivery formats.
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabinoid-based pharmaceutical, nutraceutical and cosmetic products. The company’s flagship products currently include CanChew+®, a CBD-based controlled release chewing gum, and MedChew Rx®, a combination CBD/THC gum which both provide for the treatment of pain and spasticity associated with multiple conditions.